Abstract
Recently, a mechanism of negative regulation of immune responses by a specialized population of so-called regulatory T cells (Tregs) has become a focus of intense investigation. Through the discovery of transcription factor Foxp3 as a central molecular determinant of Tregs differentiation and function, the complex biology of these cells, including maintenance of immunological tolerance to “self” and regulation of immune responses to pathogens, commensals, and tumors, has become the focus of intense investigation. The ability to control the infection and to delay the progression of the infection to AIDS and/or death is probably regulated by a balance between host factors, such as immunologic response and viral factors. Different rates of disease progression among HIV-1 infected individuals have been observed. In this context, Tregs may play an important role in the immunopathology of HIV-1 infection due to their potent suppressive activity of both T cell activation and effector function. In this review, we present the molecular and immunological aspects of Tregs in the HIV system and the association between Tregs and highly active antiretroviral therapy (HAART).
Keywords: Regulatory T cells, HIV, Foxp3, highly active antiretroviral therapy
Current HIV Research
Title: Involvement of Regulatory T Cells in HIV Immunopathogenesis
Volume: 8 Issue: 4
Author(s): Sara S. Bernardes, Isabele K. Borges, Juliana E. Lima, Paula de Azevedo O. Milanez, Ivete Conchon-Costa, Ionice Felipe, Halha O. Saridakis and Maria A.E. Watanabe
Affiliation:
Keywords: Regulatory T cells, HIV, Foxp3, highly active antiretroviral therapy
Abstract: Recently, a mechanism of negative regulation of immune responses by a specialized population of so-called regulatory T cells (Tregs) has become a focus of intense investigation. Through the discovery of transcription factor Foxp3 as a central molecular determinant of Tregs differentiation and function, the complex biology of these cells, including maintenance of immunological tolerance to “self” and regulation of immune responses to pathogens, commensals, and tumors, has become the focus of intense investigation. The ability to control the infection and to delay the progression of the infection to AIDS and/or death is probably regulated by a balance between host factors, such as immunologic response and viral factors. Different rates of disease progression among HIV-1 infected individuals have been observed. In this context, Tregs may play an important role in the immunopathology of HIV-1 infection due to their potent suppressive activity of both T cell activation and effector function. In this review, we present the molecular and immunological aspects of Tregs in the HIV system and the association between Tregs and highly active antiretroviral therapy (HAART).
Export Options
About this article
Cite this article as:
S. Bernardes Sara, K. Borges Isabele, E. Lima Juliana, de Azevedo O. Milanez Paula, Conchon-Costa Ivete, Felipe Ionice, O. Saridakis Halha and A.E. Watanabe Maria, Involvement of Regulatory T Cells in HIV Immunopathogenesis, Current HIV Research 2010; 8 (4) . https://dx.doi.org/10.2174/157016210791208613
DOI https://dx.doi.org/10.2174/157016210791208613 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
Management of HIV: Management of HIV: old challenges and new needs
The aim of this thematic issue is to provide the most recent updates regarding the effective management of HIV infection. Antiretroviral therapy (ART) has significantly decreased HIV-related mortality, leading to an enhancement in the quality of life and life expectancy for people living with HIV (PLWH). Despite the numerous advancements ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
E2F1-Mediated Apoptosis as a Target of Cancer Therapy
Current Molecular Pharmacology Radiolabeled Nanoparticles for Cancer Diagnosis and Therapy
Anti-Cancer Agents in Medicinal Chemistry Targeting Trail Towards the Clinic
Current Drug Targets The Challenge of a “Functional Cure” for AIDS by Gene Modified HSCT Therapy
Current Stem Cell Research & Therapy Population Pharmacogenomics and Personalized Medicine Research in Hungary: Achievements and Lessons Learned
Current Pharmacogenomics and Personalized Medicine Curcumin Nanomedicine: A Road to Cancer Therapeutics
Current Pharmaceutical Design Carbohydrate-Metal Complexes and their Potential as Anticancer Agents
Current Medicinal Chemistry Topoisomerase I and II Inhibitors: A Patent Review
Recent Patents on Anti-Cancer Drug Discovery Targeting the Brain: Advances in Drug Delivery
Current Pharmaceutical Biotechnology Actinium-225 in Targeted Alpha-Particle Therapeutic Applications
Current Radiopharmaceuticals Erdafitinib as a Novel and Advanced Treatment Strategy of Metastatic Urothelial Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Therapeutic Outlook of Pyrazole Analogs: A Mini Review
Mini-Reviews in Medicinal Chemistry Distribution, Bioactivities and Therapeutical Potentials of Pentagalloylglucopyranose
Current Bioactive Compounds Models of HIV-1 Persistence in the CD4+ T Cell Compartment: Past, Present and Future
Current HIV Research Inhibition of Apoptosis in Pediatric Cancer by Survivin
Current Pediatric Reviews HIV-1 Vpr: A Closer Look at the Multifunctional Protein from the Structural Perspective
Current HIV Research The Sleeping Beauty Transposon Vector System for Treatment of Rare Genetic Diseases: An Unrealized Hope?
Current Gene Therapy Nanoparticles in Cancer
Current Radiopharmaceuticals Pharmacological Approaches in an Experimental Model of Non-Small Cell Lung Cancer: Effects on Tumor Biology
Current Pharmaceutical Design Regulating TRAIL Receptor-Induced Cell Death at the Membrane: A Deadly Discussion
Recent Patents on Anti-Cancer Drug Discovery